Characteristics
Well-controlled asthma n(%*) 192(84.2) Not well-controlled asthma n(%*) 36(15.8)
P
Male 118 (89.4) 14 (10.6) 0.012
Age (yr) (median, IQR) 10.5 (8.3-12.5) 12.2 (9.6-14.4) 0.005
Duration of follow up (yr) (median, IQR) 2.1 (1.0-5.1) 3.3 (1.5-6.4) 0.180
Tobacco exposure 113 (85.6) 19 (14.4) 0.498
Aeroallergen sensitisation 99 (90.0) 11 (10.0) 0.021
Asthma therapy 0.059
As needed SABA
51 (91.1)
5 (8.9)
ICS use
127 (83.1)
26 (16.9)
ICS monotherapy
99 (83.2)
20 (16.8)
LTRA monotherapy
14 (77.8)
4 (22.2)
ICS+LTRA
16 (94.2)
1 (5.8)
ICS+LABA
12 (70.6)
5 (29.4)
ICS+LABA+LTRA
0 (0.0)
1 (100)
Asthma severity 0.167
İntermittent
53 (89.8)
6 (10.2)
Mild persistent
95 (81.2)
22 (18.8)
Moderate persisitent
33 (94.3)
2 (5.7)
Severe persistent
11 (64.7)
6 (35.3)
Allerjic rhinitis coexistent 81 (85.3) 14 (14.7) 0.695
FeNO (ppb) 19 (14-28) 19 (16-26) 0.654
PACT 23 (19-26) 18 (13.5-21) <0.001
ACT 22.5 (19.25-24.75) 15 (14-19) <0.001
PAQLQ (median, IQR) 6.1 (5.2-6.6) 4.8 (3.9-5.6) <0.001
Symptoms 5.4 (4.6-6.6) 3.8 (2.8-5.2) <0.001
Emotional functions 6.2 (5.4-6.7) 4.6 (3.8-5.4) <0.001
Activity limitation 6.4 (5.2-7.0) 5.5 (4.5-6.2) 0.001
Spirometry (median, IQR)
FEV1 (expected %)
93 (87-103)
94 (83-103)
0.757
FEV1/FVC (ratio)
0.99 (0.93-1.05)
0.97 (0.94-1.05)
0.724
FEF25-75 (expected %)
92 (79-112)
88 (79-106)
0.485